GlassScriptPhysician profile
Martha Davis
NPI 1376618736
$7,578.50
in general payments reported to CMS, 2019-2025
27 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,891 · 2023: $2,734 · 2024: $1,801 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,567.16 |
| Education | $119.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.66 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $890.63 | 2022-2025 | Caplyta |
| Corium, LLC | $810.49 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $720.03 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $612.45 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $520.11 | 2022-2025 | Rexulti, Brintellix, Abilify Asimtufii |
| Alkermes, INC. | $494.42 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $480.18 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $435.88 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $324.88 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $179.44 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $151.61 | 2024-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $126.47 | 2022 | |
| Bausch Health US, LLC | $124.87 | 2022-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $114.50 | 2022-2023 | Invega Sustenna, Invega Trinza, Spravato |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $68.17 | 2022 | |
| Sunovion Pharmaceuticals INC. | $65.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.70 | 2024-2025 | Cobenfy |
| Alfasigma USA, INC. | $33.69 | 2022 | |
| Almatica Pharma LLC | $33.44 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $31.36 | 2023 | Qelbree |
| Biogen, INC. | $20.00 | 2024 | |
| Merck Sharp & Dohme LLC | $16.49 | 2023 | Belsomra |
| Altathera Pharmaceuticals LLC | $15.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.37 | 2023 | Trintellix |
| Vertical Pharmaceuticals, LLC | $14.38 | 2024 | Relexxii |
| Idorsia Pharmaceuticals US INC | $14.00 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.